Proliferative vitreoretinopathy:: Cytologic findings in vitreous samples

被引:23
作者
Martín, F
Pastor, JC
de la Rúa, ER
Mayo-Iscar, A
García-Arumí, J
Martínez, V
Fernández, N
Saornil, MA
机构
[1] Univ Valladolid, IOBA, Retina Grp, E-47005 Valladolid, Spain
[2] Univ Valladolid, IOBA, Stat & Operat Res Dept, E-47005 Valladolid, Spain
[3] Univ Valladolid, IOBA, Miguel N Burnier Registry Ocular Pathol, E-47005 Valladolid, Spain
[4] Hosp Univ Valle Hebron, Barcelona, Spain
关键词
proliferative vitreoretinopathy; rhegmatogenous retinal detachment; vitreous cytology;
D O I
10.1159/000071175
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To compare the cellularity of vitreous samples obtained from patients with rhegmatogenous retinal detachment complicated by proliferative vitreoretinopathy (PVR) and from patients with uncomplicated rhegmatogenous retinal detachment (RD) to detect possible variations in cellularity overtime. Methods: One hundred and twenty-five vitreous specimens collected from patients with RD (n = 41) and PVR (n = 84) were processed through direct paraffin embedding and cytospin. Different cell types were identified by light-microscopy (hematoxylin-eosin and Papanicolaou stain) according to their morphologic features, and a scale of cellular density was established for each cell type. Student's t test was used to analyze differences in the cellularity of RD versus PVR. A quadratic model was used to identify variations in the density of each cellular type in the PVR group, based on its evolution time. Results: During the first months after surgery, more macrophages and fibroblast-like cells were observed in the PVR group, but at other times no differences were found. Conclusions: There are some differences in vitreous cellularity in PVR specimens when compared with RD. Especially relevant could be the large number of macrophages in earlier stages and their constant presence over time in PVR samples. The cytology of vitreous samples may shed light on the chronology of PVR cell pathobiology. Copyright (C) 2003 S. Karger AG, Basel.
引用
收藏
页码:232 / 238
页数:7
相关论文
共 32 条
[1]  
AGUIRREBENA A, 1986, ARCH SOC ESP OFTALMO, V51, P229
[2]   Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy - Results from a randomized, double-blind, controlled clinical trial [J].
Asaria, RHY ;
Kon, CH ;
Bunce, C ;
Charteris, DG ;
Wong, D ;
Khaw, PT ;
Aylward, GW .
OPHTHALMOLOGY, 2001, 108 (07) :1179-1183
[3]  
BAUDOUIN C, 1991, INVEST OPHTH VIS SCI, V32, P2065
[4]   Inflammation measurement and immunocharacterization of cell proliferation in an experimental model of proliferative vitreoretinopathy [J].
Baudouin, C ;
Khosravi, E ;
Pisella, PJ ;
Ettaiche, M ;
Elena, PP .
OPHTHALMIC RESEARCH, 1998, 30 (06) :340-350
[5]   IMMUNOCYTOLOGY OF CELLULAR-COMPONENTS IN VITREOUS AND SUBRETINAL FLUID FROM PATIENTS WITH PROLIFERATIVE VITREORETINOPATHY [J].
BAUDOUIN, C ;
HOFMAN, P ;
BRIGNOLE, F ;
BAYLE, J ;
LOUBIERE, R ;
GASTAUD, P .
OPHTHALMOLOGICA, 1991, 203 (01) :38-46
[6]  
Casaroli-Marano RP, 1999, INVEST OPHTH VIS SCI, V40, P2062
[7]   PROLIFERATIVE VITREORETINOPATHY - PATHOBIOLOGY, SURGICAL-MANAGEMENT, AND ADJUNCTIVE TREATMENT [J].
CHARTERIS, DG .
BRITISH JOURNAL OF OPHTHALMOLOGY, 1995, 79 (10) :953-960
[8]  
CHARTERIS DG, 1993, OPHTHALMOLOGY, V100, P43
[9]  
CHESS J, 1983, OPHTHALMOLOGY, V90, P1560
[10]  
COCO RM, 1996, ARCH SOC ESP OFTALMO, V70, P197